Drug results: 1

basiliximab Basiliximab functions as an IL-2 receptor antagonist by binding with high affinity to the alpha chain of the high affinity IL-2 receptor complex and inhibiting IL-2 binding. Basiliximab is specifically targeted against IL-2Ralpha, which is selectively expressed on the surface of activated T-lymphocytes. This specific high affinity binding of basiliximab to IL-2Ralpha competitively inhibits IL-2-mediated activation of lymphocytes, a critical pathway in the cellular immune response involved in allograft rejection.

Featured News

Drugcentral 2023 NAR Article

The Latest in Chemistry in Coronavirus Research


Drugs in the News


Makena Venetoclax Dapagliflozin KEYTRUDA Sacubitril LORBRENA Hydroxychloroquine


DrugCentral Search Overview